Total RNA profiles in response to nilotinib, vandetanib and mobocertinib in human induced pluripotent stem cell-derived cardiomyocytes Transcriptome. Homo sapiens

To define proarrhythmic effects mechanism of tyrosine kinase inhibitor, we measured transcriptome changes in human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) treated with TKIs associated high risk of arrhythmias, such as nilotinib, vandetanib, and mobocertinib. Gene expression changes were assessed at the cell level using total RNA-seq.Overall design hiPSC-CMs were treated with each TKI (nilotinib, vandetanib, and mobocertinib) at 3 uM for 48 hours. hiPSC-CMs were also treated with the DMSO vehicle-only control at 48h. Each treatment condition had three biological replicates, collected from three independent experiments using three different lots of hiPSC-CMs. Total RNA was collected from all these samples.